Vanguard Russell 2000 Growth ETF

Most Recent

  • uploads///AXDX RD Expenses
    Company & Industry Overviews

    What Are Accelerate Diagnostics’ Key Strengths?

    In June 2017, Accelerate Diagnostics (AXDX) raised net proceeds of $83.2 million from a public offering of 2.8 million shares of common stock.

    By Kenneth Smith
  • uploads///Chart
    Company & Industry Overviews

    A Look at Ionis Pharmaceuticals’ Nusinersen

    Ionis Pharmaceuticals (IONS) has entered into a collaborative agreement with Biogen Idec (BIIB) for the development and commercialization of nusinersen.

    By Mike Benson
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.